Stöver Lehmann Consulting

Stöver Lehmann

ConsultingBy

Manon Stöver

Matthieu Lehmann

Lausanne, June 23rd 2006

Stöver Lehmann Consulting

2

AgendaAgenda

Who are we ?Why are we here today ?What has been done until

today?What can be achieved and

how?


3

SLC – Team presentationSLC – Team

presentation Manon Stöver

Co-founder Expertise in investment within the Petroleum Industry

Matthieu Lehmann Co-founder Expertise in Biotechnologies and Process Development


4

SLC - PhilosophySLC - Philosophy

Our orientation is to raise funds for refreshing and interesting research and development

Our vision is to support ideas with huge potential for humanity

We are looking for revolution more than evolution


5

SLC – Past Successes

SLC – Past Successes

SLC’s past successes in raising funds are in the field of research and development: BioXell (Cancer therapy) 7TM Pharma (Virology) H2FUEL (hydrogen engine) HydroNEXT (biofuel cell)


6

Dr. de Grey’s presentation

Dr. de Grey’s presentation

Engineering background from computer sciences

Previous work in bioinformatics

Current research in biogerontology

His vision:

Reengineering the approach of how to cure aging


7

What is Unlimited Life?

What is Unlimited Life?

A research institute in biogerontology

A concept: Curing aging

The final mission of UL is to provide people with medecines to cure aging

Metabolism Damage Pathology

Gerontology Engineering Geriatrics


8

More about Unlimited Life

More about Unlimited Life

Home institution for research is Cambridge

Research is highly potential for several breakthroughs : ‘We are already on the road, it’s definitely more than a simple concept !’

Absolutely refreshing approach of anti-aging process: start at the roots of the process

At the beginning of something revolutionary


9

The 7 deadly things principle

The 7 deadly things principle

Basics of Dr. de Grey research

Damages rising with age1. Cell loss, cell atrophy2. Nuclear [epi]mutations (only

cancer matters)3. Mutant mitochondria4. Death-resistant cells5. Extracellular crosslinks6. Extracellular junk7. Intracellular junk


10

Today’s FocusToday’s Focus

Advise to improve funding of Unlimited Life research

Why are we concerned ? We believe in our customer competencies

We may change the world Aging is the most fatal and the first cause of death on Earth

Life is a gift, we must fight to keep it as hard as we fight for our freedom


11

Competitive Anti-Aging Researches

Competitive Anti-Aging Researches

Current technologies to slow the aging process Cryonic therapy Chemical drugs (DHEA) Medicines based on proteins

Plastic surgery Vitamins and food supplements


12

Results for current Anti-Aging

Results for current Anti-Aging

Results obtained from research Slowing down the process of aging

Mask the external signs of aging Small improvement on the origin of aging process

None of these technology treated aging from its roots

NB! These technologies are not competitive with the results of Dr. de Grey’s research


13

Origin of previous raised funds

Origin of previous raised funds

Past funds Winning the Mprize: donations for continuing research

Expenses contributions Donation of Air miles

Who are these investors ? Individuals Foundations


14

Money raised from these funds

Money raised from these funds

Funds raised Mprize: $ 3.5 million Donations: $ 218’005 Cost expenses: $ 89’756

Air miles: 360’374 milesGood starting point but obviously not

enough !


15

Dr. de Grey’s request for funding

Dr. de Grey’s request for funding

Dr. de Grey objectives: $100M/year of funding for the next 10 years

Creating research institutes all over the world

Investors are not to draw any direct benefit from providing funding


16

Possible solutionsPossible solutions

Organizational improvements

Promotion improvements Improvement of current funding ways

New funding ways


17



Organizational aspectDefine milestones/targets

Build a teamFind a ‘face’ for funding leader


18

Promotion improvements

Promotion improvements

Generate publicity Newspapers Broadcasting of documentaries

Universities Advertisements Exhibition

Nobel price for medicine


19

Improvement of current funding ways

Improvement of current funding ways

Donations

Other foundations

Individuals

Air miles


20

Foundations and Individuals

Foundations and Individuals

Aim at other foundations: AIDS association Cancer therapy association Arthritis Foundation Biological Trust

Convince individuals: Wealthy philanthropic people


21

AirmilesAirmiles

Change the law Airline companies might write off their airmiles older than 20y to foundations

Opportunity to raise billions of airmiles

Very convenient for both parties


22

New funding waysNew funding ways

Business Angels

Open source research

Partnerships

VCs


23

Business angelsBusiness angels

With certain characteristics: High personal interest in the research

Diversifying his/her investments Maybe (s)he will give a billion

Examples Donald Trump Hugh Hefner Bill Gates Larry Ellison


24

Larry EllisonLarry Ellison

Founder of Oracle

Almost as wealthy as Bill

Gates

Human benefactor

What is more prestigious

than investing in first

cause of death


25

Open sourceOpen source

No profits involvement Access to a huge community Low and shared cost Increase in time efficiency and productivity

High demanding process from a controlling aspect


26

Open source in our case

Open source in our case

Applicable on secondary level of research

Set up an association with confidential agreement

Create different virtual institutes around the world


27

PartnershipPartnership

Partners Cooperation in research; such as Cryogenics

Set up subsidiaries with pharmaceuticals

VCs with pharmaceuticals in the portfolio

Business angels with certain interests

To attract partners: certain level of leverage needed Define milestones/targets Create a source of revenues


28

Venture CapitalistVenture Capitalist

Involvement in the management and the ownership

Huge amount money can be brought on the table

Examples Cardinal Partners Polaris Venture Partners Techno Venture Management Novartis Bioventures Fund Cargill Ventures Three Arch Partners


29

Funding scheduleFunding schedule

First two years Research set up

Define milestones/targets for third parties

Alliances with anti-aging clinics to set up globally research institutes at universities

Create a team Use of benefits of an open source research

Funds Foundations and prices Business Angels Adjust budget


30

Funding scheduleFunding schedule

Next three years Involvement of VCs Creating revenues (seminars, meetings, publishing books, magazines)

Partnership with pharmaceutical companies regarding first mover advantage for commercial use


31

Financial Scheme - Sources

Financial Scheme - Sources

SourcesYear 1

Year 2

Year 3

Year 4

Year 5

Donations

0.2 0.2 0.4 0.5 0.5

VCs - - 2.1 6.9 6.8

BAs 4.3 4.3 2.0 2.0 2.0

Others 0.5 0.5 0.5 0.6 0.7

Total 5 5 5 10 10


32

Financial scheme - Uses

Financial scheme - Uses

Uses Year 1

Year 2

Year 3

Year 4

Year 5

Current expenditures

0.1 0.1 0.1 0.1 0.1

Promotion 0.1 0.1 0.5 0.5 0.5

Publishing

0.1 0.1 0.2 0.2 0.2

Research 4.5 4.5 9 9 9

Others 0.2 0.2 0.2 0.2 0.2


33

ConclusionConclusion

We have investigated

possibilities for

funding

within the requests

outside the requests

Who dares wins…

Thank for your attention

Manon Stöver: [email protected]

Matthieu Lehmann

[email protected]

mailto:[email protected]











Stöver Lehmann Consulting

Documents